Influence of alterations in forgoing life-sustaining treatment practices on a clinical sepsis trial

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Critical Care Medicine

• Publication date

  1997-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00003246-199703000-00002
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor α in Patients With Sepsis Syndrome: A Randomized, Controlled, Double-blind, Multicenter Clinical Trial

  1995cited by this paper
• Withdrawing care. Experience in a medical intensive care unit.

  1994cited by this paper
• Changing patterns of terminal care management in an intensive care unit.

  1994cited by this paper
• Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial

  1994cited by this paper
• Does prediction of outcome alter patient management?

  1993cited by this paper
• Process of forgoing life‐sustaining treatment in a university hospital: An empirical study

  1992cited by this paper
• Ordering and administration of sedatives and analgesics during the withholding and withdrawal of life support from critically ill patients.

  1992cited by this paper
• Active management of the dying patient

  1992cited by this paper
• A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative Sepsis

  1991cited by this paper
• Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.

  1991cited by this paper
• Changing attitudes and practices in foregoing life-sustaining treatments.

  1990cited by this paper
• Withholding and withdrawal of life support from the critically ill.

  1990cited by this paper
• Terminal events in the intensive care unit: review of 258 fatal cases in one year.

  1989cited by this paper
• A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock.

  1987cited by this paper
• The use and implications of do not resuscitate orders in intensive care units.

  1986cited by this paper
• Cessation of therapy in terminal illness and brain death

  1978cited by this paper

• Treatment-limiting decisions in patients with severe traumatic brain injury in the Netherlands

  2024cites this paper
• Incidence and impact of withdrawal of life-sustaining therapies in clinical trials of severe traumatic brain injury: A systematic review

  2018cites this paper
• A randomized controlled trial investigating the effects of parenteral fish oil on survival outcomes in critically ill patients with sepsis: a pilot study.

  2015cites this paper
• The difficulties of clinical trials evaluating therapeutic agents in patients with severe sepsis

  2012cites this paper
• Relationship Between the Inflammation and Coagulation Pathways in Patients with Severe Sepsis

  2012cites this paper
• Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis

  2011cites this paper
• Is worsening multiple organ failure the cause of death in patients with severe sepsis?*

  2011cites this paper
• Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis*

  2010cites this paper
• [Les directives PDR sont établies tôt chez les patients sous ventilation mécanique à l’unité des soins intensifs]

  2008cites this paper
• Treatment of sepsis: current status of clinical immunotherapy.

  2006cites this paper
• Forgoing life sustaining treatments: differences and similarities between North America and Europe

  2006cites this paper
• Underlying disorders and their impact on the host response to infection.

  2005cites this paper
• DNR directives are established early in mechanically ventilated intensive care unit patients

  2004cites this paper
• End-of-life practices in European intensive care units.

  2003cites this paper
• The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results*

  2003cites this paper
• End-of-life practices in European intensive care units: the Ethicus Study.

  2003cites this paper
• The Ethicus Study End-of-Life Practices in European Intensive Care Units : Correction

  2003cites this paper
• Sepsis: menu of new approaches replaces one therapy for all.

  2002cites this paper
• Strong vasopressor support may be futile in the intensive care unit patient with multiple organ failure

  2000cites this paper
• Meningococcemia as a model for testing the hypothesis of antisepsis therapies

  2000cites this paper
• Use of a screen log to audit patient recruitment into multiple randomized trials in the intensive care unit

  2000cites this paper
• Bioethical issues related to continuous renal replacement therapy in intensive care patients

  2000cites this paper
• Sepsis and MODS - What Is Wrong and What Is Right

  1999cites this paper
• Sepsis and Organ Dysfunction

  1999cites this paper
• Forgoing life support in western European intensive care units: the results of an ethical questionnaire.

  1999cites this paper
• The failure of clinical trials in sepsis: Challenges of clinical trial design

  1999cites this paper
• Forgoing life-sustaining treatment in an Israeli ICU

  1998cites this paper
• Receptor Blocking Agents: Why Did They Fail?

  1998cites this paper
• Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group.

  1998cites this paper
• Design of clinical trials in sepsis: problems and pitfalls.

  1998cites this paper
• How to use an article on therapy or prevention: pneumonia prevention using subglottic secretion drainage.

  1997cites this paper